Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Kainos FY revenues seen at upper end of consensus

(Sharecast News) - IT provider Kainos Group said on Monday that it now anticipates full-year revenues to be at the upper end of consensus forecasts, driven by "stronger sales" in the period. Kainos said revenues would be at the higher end of revenue estimates of £378.0m to £393.4m, while adjusted pre-tax profits were expected to be in line with current consensus forecasts of between £65.1m and £74.7m.

The FTSE 250-listed firm said its "sales success" was creating opportunities for further operating progress during the rest of the financial year, and noted that with new projects mobilising across all three divisions, it was recruiting additional staff, as well as increasing its short-term use of contractors to support both growth and its strong pipeline.

Kainos' Workday Products division continued to deliver "strong growth", passing the $100m annual recurring revenue milestone in July and returning it to growth, while its Digital Services arm secured "several significant programmes" in both healthcare and the public sector, including contracts in the Home Office, NHS England, and the Driver and Vehicle Standards Agency.

"Although the macroeconomic environment has improved, volatility persists, and we continue to balance growth, international expansion, investment and profitability against this backdrop," said Kainos.

"Kainos continues to operate in markets with clear long-term structural drivers, including the emerging opportunities from wider AI adoption. We remain confident in our strategy to capture and deliver on these opportunities. Backed by a robust backlog, healthy pipeline, solid balance sheet, disciplined capital allocation, and strong cash flow, we have a firm foundation from which to drive long-term shareholder value."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.